High level of fatigue in lymphoma patients treated with high dose therapy

Journal of Pain and Symptom Management

Volumn 19, Issue 6, 2000, Pages 446-456

  Knobel, Heidi ^a   Loge, Jon Håvard ^a,b   Nordøy, Tone ^c   Kolstad, Arne L ^c   Espevik, Terje ^a   Kvaløy, Stein ^a,d,e   Kaasa, Stein ^a,d,e  

^a NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d OSLO UNIVERSITY HOSPITAL   (Norway)

^e TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

Author keywords

Autologous bone marrow transplantation; Cancer; Cytokines; Fatigue; High dose therapy; Quality of life; Sex hormones

Indexed keywords

CARMUSTINE; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; INTERLEUKIN 6; METHOTREXATE; PREDNISONE; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR RECEPTOR; VINCRISTINE;

ADULT; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FATIGUE; FEMALE; HUMAN; LYMPHOMA; MALE; QUALITY OF LIFE; QUESTIONNAIRE; SELF REPORT; SEX DIFFERENCE;

EID: 0033949865     PISSN: 08853924     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0885-3924(00)00144-5     Document Type: Article

References (49)

1. Sociè G., Henry-Amar M., Divergie A., Esperou-Bordeau H., Ribaud P., Traineau R., Gluckman E. Malignant diseases after allogenic bone marrow transplantation. an updated overview Nov Rev Fr Hematol. 36(Suppl 1):1994;75-77.
2. Vose J.M., Kennedy B.C., Bierman P.J., Kessinger A., Armitage J.O. Long-term sequelae of autologous bone marrow or peripheral stem cell transplantation for lymphoid malignancies. Cancer. 69:1992;784-789.
3. van Dam F.S.A.M., Schagen S.S., Muller M.J., Boogerd W., vd Wall E., Droogleever Fortuyn M.E., Rodenhuis S. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer. high-dose versus standard-dose chemotherapy J Natl Cancer Inst. 90:1998;210-218.
4. Deeg J.H. Delayed complications and long-term effects after bone marrow transplantation. Bone Marrow Transplant. 4:1990;641-657.
5. Hjermstad M.J., Kaasa S. Quality of Life in adult cancer patients treated with bone marrow transplantation - a review of the literature. Eur J Cancer. 31A:1995;163-173.
6. Hjermstad M.J., Evensen S.A., Kvaløy S.O., Kaasa S. Health related quality of life after allogenic or autologous stem cell transplantation. a prospective study J Clin Oncol. 17:1999;706-718.
7. Hjermstad M.J., Holthe H., Evensen S.A., Fayers P., Kaasa S. Do patients who are treated with stem cell transplantation have a health related quality of life comparable to the general population after one year? Bone Marrow Transpl. 124:1999;911-918.
8. Andrykowski M.A., Carpenter J.S., Greiner C.B., Altmeier E.M., Burish T.G., Antin J.H., Gingrich R., Cordova M.J., Henslee-Downey P.J. Energy level and sleep quality following bone marrow transplantation. Bone Marrow Transplant. 20:1997;669-679.
9. Aaronsen N.K., Ahmedzai S., Bergman B., Bullinger M., Cull A., Duez N.I., Filiberti A., Flechtner H., Fleishman S.B., Haes J.C.et al. The European Organization for Research and Treatment of Cancer QLQ-C30. A quality of life instrument for use in international clinical trials in oncology J Natl Cancer Inst. 85:1993;365-376.
10. Wessely S. The measurement of fatigue and chronic fatigue syndrome. J R Soc Med. 85:1992;189-190.
11. Wettergren L., Langius A., Björkholm M., Björvell H. Physical and psychosocial functioning in patients undergoing autologous bone marrow transplantation - a prospective study. Bone Marrow Transplant. 20:1997;497-502.
12. Bush N.E., Haberman M., Donaldson G., Sullivan K.M. Quality of life of 125 adults surviving 6-18 years after bone marrow transplantation. Soc Sci Med. 40:1995;479-490.
13. Andrykowski M.A., Altmaier E.M., Barnett R.L., Otis M.L., Gingrich R., Henslee-Downey P.J. The quality of life in adult survivors of allogenic bone marrow transplantation. correlates and comparison with matched renal transplant recipients Transplantation. 50:1990;399-406.
14. Belec R.H. Quality of life. perceptions of long-term survivors of bone marrow transplantation Oncol Nurs Forum. 19:1992;31-37.
15. Chalder T., Berelowitz G., Pawlikowska T., Watts L., Wessely S., Wright D., Wallace E.P. Development of a fatigue scale. J Psychosom Res. 37:1993;147-153.
16. Loge J.H., Ekeberg Ø, Kaasa S. Fatigue in the general Norwegian population. Normative data and associations J Psychosom Res. 45:1998;53-65.
17. Loge J.H., Abrahamsen A.F., Ekeberg Ø, Kaasa S. Hodgkins disease survivors more fatigued than the general population. J Clin Oncol. 17:1999;253-261.
18. Richardson A. Fatigue in cancer patients. a review of the literature Eur J Cancer Care. 4:1995;20-32.
19. Smets E.M.A. Fatigue in cancer patients. Br J Cancer. 68:1993;220-224.
20. Darko D., McCutchan A., Kripke D., Gillin J., Golchan S. Fatigue, sleep disturbance, disability, and indicies of progression of HIV infection. Am J Psychiatry. 194:1992;514-519.
21. Wysenbeek A.J., Leibovici L., Weinberger A., Guedj D. Fatigue in systemic lupus erythematosus. Prevalence and relation to disease expression. Br J Rheumatol. 32:1993;633-635.
22. Greenberg D.B., Gray J.L., Mannis C.M., Eisenthal S., Carey M. Treatment-related fatigue and serum interleukin-1 levels in patients during external beam irradiation for prostate cancer. J Pain Symptom Manage. 8:1993;196-200.
23. Arnason B.G.W. Nervous system - Immune System Communication. Rev Infec Diseases. 13(Suppl 1):1991;134-137.
24. Shimmer A., Quatremain M., Imre K., Ali V., McCrae J., Stewart K., Crump M., Derzko C., Keating A. Ovarian function after autologous bone marrow transplantation. J Clin Oncol. 16:1998;2359-2363.
25. Todd B.D. Pancreatic carcinoma and low serum testosterone; a correlation secondary to cancer cachexia? Eur J Surg Oncol. 14:1988;199-202.
26. Chlebowski R.T., Heber D. Hypogonadism in male patients with metastatic cancer prior to chemotherapy. Cancer Res. 42:1982;2495-2498.
27. Wessely S., Powell R. Fatigue syndromes. a comparison of chronic "postviral" fatigue with neuromuscular and affective disorders J Neurol Neurosurg Psychiatry. 52:1989;940-948.
28. Fayers P, Aaronsen N, Bjordal K, Sullivan M. EORTC QLQ-C30 Scoring Manual. EORTC Quality of life study group. Brussels, Belgium, 1995.
29. Hjermstad M.J., Fayers P.M., Bjordal K., Kaasa S. Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire. The QLQ-C30 (+3) J Clin Oncol. 16:1998;1188-1196.
30. Aarden L.A., de Groot E.R., Shaap O.L., Landsdorp P.M. Production of hybridoma growth factor by human monocytes. Eur J Immunol. 7:1987;1441.
31. Mosman T. Rapid colorimetric assay for cellular growth and survival. application to proliferation and cytotoxic assays J Immunol Methods. 65:1983;55.
32. Espevik T., Nissen-Meyer J. A highly sensitive cell line, WEHI 164 clone 13, for measuring cytotoxic factor/tumor necrosis factor from hman monocytes. J Immunol Methods. 95:1986;99.
33. Liabakk N.B., Sundan A., Lien E., Lacgried A., Bombac M.P., Ranges G., Espevik T. The release of p55 receptor from U937 cells studied by a new p55 immunoassay. J Immunol Methods. 163:1993;145-154.
34. Osoba D., Rodrigues G., Myles J., Zee B., Pater J. Interpreting the significance of changes in health-related-quality-life-scores. J Clin Oncol. 16:1998;139-144.
35. Fobair P., Hoppe R.T., Bloom J., Cox R., Varghese A., Spiegel D. Psychosocial problems among survivors of Hodgkins disesase. J Clin Oncol. 4:1986;805-814.
36. Sutherland H.J., Fyles G.M., Adams G. Quality of life following bone marrow transplantation. a comparison of patients reports with population norms Bone Marrow Transplant. 17:1997;1129-1136.
37. Denz H., Orth B., Wiess G., Gallati H., Herrmann R., Huber P., Wachter H., Fuchs D. Serum soluble Tumor Necrosis Factor receptor 55 is increased in patients with heamatological neoplasias and is associated with immune activation and weight loss. Eur J Cancer. 29A(16):1993;2232-2235.
38. Warzocha K., Salles G., Bienvenu J., Bastian Y., Dumontet C., Renard N., Neidhardt-Berard E., Coiffier B. Tumor Necrosis Factor ligand-receptor system can predict treatment outcome in lymphoma patients. J Clin Oncol. 15:1997;499-508.
39. Salles G., Bienvenu J., Bastion Y., Barbier Y., Doche C., Warsocha K., Gutowski M., Rieux C., Coifier B. Elevated circulating levels of TNFα and its soluble receptor are associated with an adverse prognosis in lymphoma patients. Br J Haematol. 93:1960;352-359.
40. Patarca R., Klimas N.G., Lugtendorf S., Antoni M., Fletcher M.A. Dysregulated expression of tumor necrosis factor in chronic fatigue syndrome. interrelations with cellular sources and patterns of soluble immune mediator expression Clin Infect Dis. 18(Suppl 1):1994;147-153.
41. Landay A.L., Jessop C., Lennete E.T., Mevy J.A. Chronic fatigue syndrome. clinical conditions associated with immune activation Lancet. 338:1991;707-712.
42. Linde A., Andersson B., Svenson S.B., Ahrne H., Carlsson M.P., Forsberg P., Hugo H., Kerstorp A., Lenkei R., Lindwall A., Loftenius A., Säll C., Anderson J. Serum levels of lymphokines and soluble cellular receptors in primary Epstein-Barr virus infection and in patients with chronic fatigue syndrome. J Infect Dis. 165:1992;994-1000.
43. Morant R. Asthenia. an important symptom in cancer patients Cancer Treat Rev. 22(Suppl.A):1996;117-221.
44. Keilholz U., Korbling M., Fehrentz D., Bauer H., Hunstein W. Long term endocrine toxicity of myeloablative treatment followed by autologous bone marrow / blood-derived stem cell transplantation in patients with malignant lymphohematopoietic disorders. Cancer. 64:1989;641-645.
45. Studd J.W.W., Smith R.N.J. Oestradiol and testosterone implants. Baillieres Clin Endocrinol Metab. 7:1993;203-223.
46. Cull A., Hay C., Love S.B., Mackie M., Smets E., Stewart M. What do cancer patients mean when they complain of concentration and memory problems? Br J Cancer. 74:1996;1674-1679.
47. van Tulder M.W., Aaronson N.K., Bruning P.F. The quality of life of long term survivors of Hodgkins disease. Ann Oncol. 5:1994;153-158.
48. Andrykowski M.A., Altmaier E.M., Barnett R.L., Burish T.G., Gingrich R., Henslee-Downey P.J. Cognitive dysfunction in adult survivors of allogenic marrow transplantation. relationship to dose of total body irradiation Bone Marrow Transplant. 6:1990;269-276.
49. Loge J.H., Abrahamsen A.F., Ekeberg Ø, Kaasa S. Fatigue and psychiatric morbidity among Hodgkin's disease survivors. J xcPain Symp Manag. 19:2000;91-99.